# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 bill...
Paying Attention To Gold Miners On Zero Hedge on Monday, contributing editor “Quoth The Raven” suggested “paying urgent attent...
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"...
-Bloomberg
Cantor Fitzgerald analyst Charles Duncan reiterates Reata Pharmaceuticals (NASDAQ:RETA) with a Neutral and maintains $172 pr...